New weight-loss shot appears to outperform other obesity drugs on market
Eli Lilly has announced that its new weight-loss drug, retatrutide, has shown significant effectiveness in a recent trial. Participants lost an average of 28% of their body weight over 80 weeks, outperforming other obesity medications. The drug, administered via injection, also reported various side effects among users.
- ▪Retatrutide led to an average weight loss of 70.3lbs (28.3%) among participants receiving the 12mg dose.
- ▪In the trial, 65.3% of participants on the 12mg regimen reduced their BMI below 30.
- ▪Patients on retatrutide reported side effects such as nausea, diarrhea, and vomiting, with incidence increasing with dosage.
Opening excerpt (first ~120 words) tap to expand
Eli Lilly’s office in San Diego, California, on 17 September 2020. Photograph: Mike Blake/ReutersView image in fullscreenEli Lilly’s office in San Diego, California, on 17 September 2020. Photograph: Mike Blake/ReutersWeight-loss drugsNew weight-loss shot appears to outperform other obesity drugs on marketEli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugsMaya YangThu 21 May 2026 12.50 EDTLast modified on Thu 21 May 2026 12.51 EDTSharePrefer the Guardian on GoogleA new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced Thursday.The Indiana-based pharmaceutical company in a…
Excerpt limited to ~120 words for fair-use compliance. The full article is at World news | The Guardian.
Discussion
0 commentsMore from World news | The Guardian
